Introduction
There is accumulating evidence that common genetic factors might predispose to multiple autoimmune diseases. Recently, PTPN22 (R620W) gene polymorphism was demonstrated to be associated with type I diabetes, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Grave's disease. [1] [2] [3] [4] [5] T variant of PTPN22 1858 C/T single-nucleotide polymorphism disrupts the physiological interaction between LYP protein, the lymphoid-specific tyrosine phosphatase encoded by PTPN22 gene and Csk kinase, a physical association that leads to T-cell receptor signaling inhibition. 6 Interestingly, onethird of first-degree relatives of patients with primary Sjö gren's syndrome (pSS) suffer from other autoimmune diseases, including type I diabetes, SLE and autoimmune thyroiditis. 7 We decided to investigate in a case-control study whether PTPN22 gene polymorphism was also involved in the genetic predisposition to pSS.
Results and discussion
In all, 183 Caucasian patients with pSS according to American-European consensus group criteria (which include a focus score X1 on labial salivary gland, or the presence of anti-SSA(Ro) or anti-SSB(La) antibodies) were consecutively recruited from three French reference centers (Departments of Rheumatology of Bicêtre Hospital, Lille, Le Mans). DNA samples were also obtained from 172 healthy, unrelated, French bone marrow donors. All patients and controls were Caucasians. Genomic DNA was isolated from peripheral blood mononuclear cells and analyzed by polymerase chain reaction-restriction fragment length polymorphism method, as described previously. 1 Significance values were obtained using w 2 . The number of patients with pSS and controls yielded a statistical power of 56% to exclude a genotypic relative risk of 2.0 at the 5% significance level, with minor allele risk frequency of 7.8%.
The allele and genotype frequencies in patients and controls are illustrated in Table 1 . The distribution was consistent with Hardy-Weinberg equilibrium. No significant differences in allele and genotype frequencies of PTPN22 polymorphism were detected between patients with pSS and controls ( Table 1) . No significant difference was observed in terms of clinical presentation (38.5 and 41.2% of extraglandular involvement in T and C allele carriers, respectively, P ¼ 0.78). PTPN22 gene polymorphism was not involved in genetic predisposition to a specific pattern of autoantibody secretion either (Table 2) . Thus, T allele frequency was not significantly higher in patients with anti-SSA/anti-SSB and anti-SSA alone (9 and 8.19%, respectively, vs 6.25% in patients without antibodies, P ¼ 0.24). The proportions of rheumatoid factor-positive patients did not differ significantly between T and C allele carriers (50 and 60.6%, respectively, P ¼ 0.29).
The present study was the first to investigate the role of 1858 C/T polymorphism of PTPN22 in patients with pSS. This genetic polymorphism was neither associated with predisposition to the disease nor to a specific pattern of autoantibody secretion. The T allele frequency was present in 7.8% of controls in our study, which is very similar to that observed in other Caucasian populations of European origins. 8 Moreover, since most of the genetic predisposition to pSS is related to the pattern of autoantibody secretion, 9, 10 the association between PTPN22 polymorphism and autoantibody secretion was studied. No significant association was observed regarding anti-SSA/SSB and RF secretion.
The limitation of the study consists in the fact that it is a case-control association study, which could not have enough power to detect a difference between SS and controls. However, our sample size is the largest ever analyzed in genetic studies of pSS. Such case-control strategies with a lower number of patients were successfully used in previous studies to demonstrate associations between HLA and cytokine polymorphisms and pSS. 9, 10 Thus, the results would not change in our view even with a larger sample size.
Recent results from the multiple autoimmune disease genetics consortium (MADGC) confirmed the association between PTPN22 polymorphism and four separate autoimmune phenotypes: type I diabetes, RA, SLE and Hashimoto thyroiditis. 11 However, no genetic association was found with multiple sclerosis, which confirms the results from a previous study.
8 PTPN22 polymorphism was not associated with psoriasis either.
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The 1858 C/T polymorphism of PTPN22 gene is not involved in genetic predisposition to pSS. This suggests that a common underlying etiologic pathway involving PTPN22 does not exist for all autoimmune diseases. Results are expressed as the number of patients (%).
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